CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

BACKGROUND: This study sought to compare the benefits and safety of agents including Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, and histone deacetylase (HDAC) inhibitors as second-line treatments for these patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Danyang, Luo, Yang, Wang, Jiayu, Chen, Shanshan, Lan, Bo, Ma, Fei, Xu, Binghe, Fan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463765/
https://www.ncbi.nlm.nih.gov/pubmed/37644396
http://dx.doi.org/10.1186/s12885-023-11290-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463765/
https://www.ncbi.nlm.nih.gov/pubmed/37644396
http://dx.doi.org/10.1186/s12885-023-11290-7

Ejemplares similares